Clinical trial
Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00047203 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00047203 |
|---|---|
| Title | Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | A Phase II Study of Flavopiridol in Patients With Relapsed and Refractory Multiple Myeloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma |
| Intervention type | Drug |
| Interventions | alvocidib |
| Enrollment | 35 |
| Start date | Sep 1, 2002 |
| Primary completion | Sep 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: